(Q35196999)

7 August 2017

title

Butein, a novel dual inhibitor of MET and EGFR, overcomes gefitinib-resistant lung cancer growth (English)

1 reference

7 August 2017

11

Ki Won Lee

1 reference

7 August 2017

10

Hyong Joo Lee

1 reference

7 August 2017

9

Ann M Bode

1 reference

7 August 2017

12

Zigang Dong

1 reference

7 August 2017

8

Hanyong Chen

1 reference

7 August 2017

1

Sung Keun Jung

1 reference

7 August 2017

4

Sung Young Lee

1 reference

7 August 2017

Mee-Hyun Lee

2

1 reference

7 August 2017

Do Young Lim

3

1 reference

7 August 2017

Chul-Ho Jeong

5

1 reference

7 August 2017

Jong Eun Kim

6

1 reference

7 August 2017

Tae Gyu Lim

7

1 reference

7 August 2017

publication date

29 June 2014

1 reference

7 August 2017

published in

Molecular Carcinogenesis

1 reference

7 August 2017

volume

54

1 reference

7 August 2017

issue

4

1 reference

7 August 2017

page(s)

322-331

1 reference

7 August 2017

cites work

Global cancer statistics

1 reference

ERBB receptors and cancer: the complexity of targeted inhibitors

21 January 2018

1 reference

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

21 January 2018

1 reference

An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.

21 January 2018

1 reference

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

21 January 2018

1 reference

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

MET signalling: principles and functions in development, organ regeneration and cancer

21 January 2018

1 reference

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

21 January 2018

1 reference

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

21 January 2018

1 reference

Cancer chemoprevention with dietary phytochemicals

21 January 2018

1 reference

Molecular targets of phytochemicals for cancer prevention

21 January 2018

1 reference

Butein inhibits the migration and invasion of SK-HEP-1 human hepatocarcinoma cells through suppressing the ERK, JNK, p38, and uPA signaling multiple pathways

21 January 2018

1 reference

Butein downregulates chemokine receptor CXCR4 expression and function through suppression of NF-κB activation in breast and pancreatic tumor cells.

21 January 2018

1 reference

Butein downregulates phorbol 12-myristate 13-acetate-induced COX-2 transcriptional activity in cancerous and non-cancerous breast cells

21 January 2018

1 reference

7,3',4'-Trihydroxyisoflavone, a metabolite of the soy isoflavone daidzein, suppresses ultraviolet B-induced skin cancer by targeting Cot and MKK4.

21 January 2018

1 reference

Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor

21 January 2018

1 reference

Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases

21 January 2018

1 reference

21 January 2018

The Protein Data Bank

1 reference

Myricetin suppresses UVB-induced skin cancer by targeting Fyn.

21 January 2018

1 reference

Chemotherapy for advanced non-small cell lung cancer patients with performance status 2.

21 January 2018

1 reference

Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

21 January 2018

1 reference

UCSF Chimera--a visualization system for exploratory research and analysis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/MC.22191

1 reference

7 August 2017

1 reference